Literature DB >> 12716488

Inflammatory liver steatosis caused by IL-12 and IL-18.

Masaya Kaneda1, Shin-Ichiro Kashiwamura, Haruyasu Ueda, Koji Sawada, Ayako Sugihara, Nobuyuki Terada, Akiko Kimura-Shimmyo, Yoshihiro Fukuda, Takashi Shimoyama, Haruki Okamura.   

Abstract

Acute fatty degeneration in the liver is caused by various agents, such as aspirin, valproic acid, and ibuprofen, that directly inhibit mitochondrial beta-oxidation of fatty acid and oxidative phosphorylation. Endogenous molecules, such as cytokines and hormones, are also known to mediate microvesicular steatosis in liver failure. In this study, we examined how interleukin-12 (IL-12) and IL-18 cause steatosis in the liver. Administration of these cytokines in combination caused marked hepatosteatosis and weight loss in mice. There were marked increases in levels of interferon-gamma (IFN-gamma), nitrite (NO(2)/NO(3)), and fibrinogen in the circulation in these mice. On the other hand, the ATP concentration and blood flow in the liver were significantly reduced. These changes, except the production of IFN-gamma and NO, were partially inhibited by Z-VAD-fmk, a synthetic tripeptide inhibitor for NO-induced caspases. These results indicate that IL-12 and IL-18 may mediate inflammatory hepatosteatosis through impairment of the microcirculation, which leads to mitochondrial dysfunction in hepatocytes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12716488     DOI: 10.1089/107999003321532493

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  7 in total

Review 1.  Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology.

Authors:  José Tuñón; Lina Badimón; Marie-Luce Bochaton-Piallat; Bertrand Cariou; Mat J Daemen; Jesus Egido; Paul C Evans; Imo E Hoefer; Daniel F J Ketelhuth; Esther Lutgens; Christian M Matter; Claudia Monaco; Sabine Steffens; Erik Stroes; Cécile Vindis; Christian Weber; Magnus Bäck
Journal:  Cardiovasc Res       Date:  2019-01-01       Impact factor: 10.787

2.  Murine gamma herpes virus 68 infection promotes fatty liver formation and hepatic insulin resistance in C57BL/6J mice.

Authors:  Lei Zhao; Ya-Xi Chen; Zac Varghese; Ai-Long Huang; Ren-Kuan Tang; Bei Jia; John F Moorhead; Jian-Ping Gong; Xiong Z Ruan
Journal:  Hepatol Int       Date:  2011-06-24       Impact factor: 6.047

3.  Adipose tissue dysfunction signals progression of hepatic steatosis towards nonalcoholic steatohepatitis in C57BL/6 mice.

Authors:  Caroline Duval; Uwe Thissen; Shohreh Keshtkar; Bertrand Accart; Rinke Stienstra; Mark V Boekschoten; Tania Roskams; Sander Kersten; Michael Müller
Journal:  Diabetes       Date:  2010-09-21       Impact factor: 9.461

4.  CCR5 and CXCR3 are dispensable for liver infiltration, but CCR5 protects against virus-induced T-cell-mediated hepatic steatosis.

Authors:  P J Holst; C Orskov; K Qvortrup; J P Christensen; A R Thomsen
Journal:  J Virol       Date:  2007-07-11       Impact factor: 5.103

5.  Kupffer cell and interleukin-12-dependent loss of natural killer T cells in hepatosteatosis.

Authors:  Michael Kremer; Emmanuel Thomas; Richard J Milton; Ashley W Perry; Nico van Rooijen; Michael D Wheeler; Steven Zacks; Michael Fried; Richard A Rippe; Ian N Hines
Journal:  Hepatology       Date:  2010-01       Impact factor: 17.425

6.  The effects of prenatal metformin on obesogenic diet-induced alterations in maternal and fetal fatty acid metabolism.

Authors:  Kemoy Harris; Neeraj Desai; Madhu Gupta; Xiangying Xue; Prodyot K Chatterjee; Burton Rochelson; Christine N Metz
Journal:  Nutr Metab (Lond)       Date:  2016-08-22       Impact factor: 4.169

7.  Cleavage of DNA and RNA by PLD3 and PLD4 limits autoinflammatory triggering by multiple sensors.

Authors:  Amanda L Gavin; Deli Huang; Tanya R Blane; Therese C Thinnes; Yusuke Murakami; Ryutaro Fukui; Kensuke Miyake; David Nemazee
Journal:  Nat Commun       Date:  2021-10-07       Impact factor: 17.694

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.